Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Short Interest Update

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) saw a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 736,300 shares, an increase of 462.1% from the January 31st total of 131,000 shares. Based on an average daily volume of 1,410,000 shares, the days-to-cover ratio is presently 0.5 days. Approximately 5.9% of the shares of the company are sold short.

Institutional Trading of Cyclo Therapeutics

An institutional investor recently bought a new position in Cyclo Therapeutics stock. Two Sigma Securities LLC purchased a new stake in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 42,541 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned 0.15% of Cyclo Therapeutics at the end of the most recent reporting period. 68.55% of the stock is currently owned by institutional investors.

Cyclo Therapeutics Stock Down 2.0 %

Shares of CYTH stock traded down $0.02 during trading on Friday, reaching $0.76. 26,744 shares of the company’s stock were exchanged, compared to its average volume of 2,327,837. The firm’s fifty day moving average price is $0.77 and its 200-day moving average price is $0.76. Cyclo Therapeutics has a twelve month low of $0.55 and a twelve month high of $1.79. The stock has a market capitalization of $24.85 million, a PE ratio of -0.84 and a beta of -0.49.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.